A5020371152- Vaccine Coverage and Hesitancy
- Child and Adolescent Health
- Viral gastroenteritis research and epidemiology
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Global Health Care Issues
- Eosinophilic Esophagitis
- HIV, Drug Use, Sexual Risk
- HIV/AIDS Research and Interventions
- Adolescent and Pediatric Healthcare
- HIV Research and Treatment
RTI Health Solutions
2022-2024
Triangle
2024
We evaluated the economic impact of routine childhood immunization in United States, reflecting updated vaccine recommendations and recent data on epidemiology coverage rates.An model followed 2017 US birth cohort from through death; was modeled via a decision tree for each vaccines recommended children by Advisory Committee Immunization Practices as (with annual influenza considered scenario analysis). Using information historic prevaccine vaccine-era incidence disease costs, we calculated...
Objective We evaluated the public health impact and return on investment of Belgium’s pediatric immunization program (PIP) from both healthcare-sector societal perspectives. Methods developed a decision analytic model for 6 vaccines routinely administered in Belgium children aged 0–10 years: DTaP-IPV-HepB-Hib, DTaP-IPV, MMR, PCV, rotavirus, meningococcal type C. used separate trees to each 11 vaccine-preventable pathogens: diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae...
Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HIV)-1 infection based on HIV Prevention Trials Network (HPTN) 083 and HPTN 084 clinical trials, which demonstrated superior reduction HIV-1 acquisition compared with daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) men who have sex (MSM), transgender women (TGW), cisgender women. A...
This study aims to evaluate the epidemiological impact and return on investment of pediatric immunization program (PIP) in Poland from healthcare-sector societal perspectives.A health-economic model was developed focusing nine vaccines, targeting 11 pathogens, recommended by public health authorities for children aged 0-6 years Poland. The 2019 birth cohort (388,178) followed over their lifetime, with estimating discounted outcomes, life-years gained, quality-adjusted life-years, direct...
Objectives We conducted a cost-benefit analysis of the pediatric National Immunization Program (NIP) in Italy.